| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,604 |
12,611 |
$1.14M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,497 |
17,366 |
$1.04M |
| 99051 |
|
30,010 |
28,092 |
$879K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,219 |
1,195 |
$73K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,493 |
1,240 |
$49K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
485 |
468 |
$48K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
159 |
158 |
$28K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,482 |
2,284 |
$25K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
12 |
12 |
$499.20 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$232.36 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,080 |
1,051 |
$151.46 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
12 |
12 |
$14.40 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
363 |
345 |
$5.23 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
143 |
103 |
$0.00 |